Drug profile · INN
enasidenib mesylate
IDHIFA
enasidenib mesylate (IDHIFA) is a isocitrate dehydrogenase [nadp], mitochondrial inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — enasidenib mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 6
- Programs
- 4
- Data quality
- 0.84
Quick answer
enasidenib mesylate (IDHIFA) is a isocitrate dehydrogenase [nadp], mitochondrial inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Isocitrate dehydrogenase [NADP], mitochondrial inhibitor
Primary target: Isocitrate dehydrogenase [NADP], mitochondrial
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related patents
-
US 10610125
Methods and compositions for cell-proliferation-related disorders
granted -
US 10294215
Therapeutically active compounds and their methods of use
granted -
US 10093654
Therapeutically active compounds and their methods of use
granted -
US 9738625
Therapeutically active compounds and their methods of use
granted -
US 9732062
Therapeutically active compounds and their methods of use
granted -
US 9512107
Therapeutically active compositions and their methods of use
granted
Frequently asked questions
What is enasidenib mesylate?
enasidenib mesylate (IDHIFA) is a isocitrate dehydrogenase [nadp], mitochondrial inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for enasidenib mesylate?
IDHIFA is a marketed brand name for enasidenib mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of enasidenib mesylate?
enasidenib mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.